Institutional Fund Portfolio Rebalancing
Bridge City Capital Actively Adjusts Portfolio, Boosting Hawkins and Omnicell While Reducing Other Stakes
Anonymous
Key Points
1
In Hawkins, other institutional investors posted specific increases during the quarter, including Vanguard Group (+1.4%, to 1,525,789 shares), State Street (+11.6%, to 1,067,451 shares), Wasatch Advisors (+31.4%, to 552,419 shares), Geode Capital (+2.8%, to 513,535 shares), and Capital World Investors (+34.4%, to 477,985 shares).
2
Hawkins trading context cited with the filing coverage: the stock opened at $158.34 and was referenced with a 50-day moving average of $157.54 and a 200-day moving average of $149.07.
3
For Omnicell, the reporting included key balance-sheet and valuation metrics: quick ratio 1.29, current ratio 1.50, debt-to-equity 0.13, beta 0.97, market capitalization about $1.72 billion, and P/E 85.98 (with a 12-month range of $26.84 to $55.00).
4
Plexus insider sale details were provided: insider Victor (Pang Hau) Tan sold 3,000 shares on May 11 at an average price of $271.23 for a total transaction value of $813,690, and was reported to still hold 10,457 shares after the sale.
5
Analyst commentary on Hawkins was also cited: BWS Financial reiterated a “buy” rating and set a $200.00 price target, while Weiss Ratings was reported to have downgraded Hawkins from a “buy (b-...)” rating (the downgrade details were partially truncated in the source excerpt).
Bridge City Capital LLC, a Lake Oswego, Oregon-based investment manager, bought 12,354 shares of Hawkins, Inc. worth about $1.76 million, according to MarketBeat. The purchase gives the firm roughly 0.06% of the specialty chemicals company, as large institutional investors continue to pile into the stock.
The move was part of a broader reshuffling in Bridge City's portfolio. The firm boosted its Omnicell stake by 46.3% while cutting its Albany International position by 36.5%, signaling a shift away from industrial manufacturing and toward healthcare technology, Quiver Quantitative reported.
Big Institutions Keep Buying Into Hawkins Stock
Bridge City was far from alone in adding Hawkins shares. MarketBeat reported that Vanguard Group raised its stake 1.4% to 1,525,789 shares. State Street went further, boosting its position 11.6% to 1,067,451 shares. Wasatch Advisors jumped 31.4% to 552,419 shares, and Capital World Investors surged 34.4% to 477,985 shares.
Hawkins stock opened at $158.34, sitting just above its 50-day moving average of $157.54. Its 200-day moving average stands at $149.07, suggesting steady upward momentum. BWS Financial analyst Hamed Khorsand kept a "Buy" rating on the stock with a $200 price target. He said "Hawkins stands to benefit from leveraging its domestically sourced inventory" amid global trade disruptions, according to Investing.com.
Hawkins Acquisition Spree Sparks Valuation Debate
Hawkins has completed six acquisitions in fiscal 2026, including its largest-ever deal, the purchase of WaterSurplus. CEO Patrick H. Hawkins said the firm's Water Treatment segment grew 21% year-over-year. But the buying spree has come at a cost. Annual interest and amortization expenses jumped from roughly $4–5 million to over $13 million, according to Dividend Power.
That rising debt load prompted Weiss Ratings to downgrade Hawkins from "Buy (B-)" to "Hold (C+)" in early June. Critics argue the company's P/E ratio of about 32.83 reflects M&A-driven growth rather than organic margin gains. "The rapid M&A is resulting in rising amortization and depreciation costs affecting EPS," one analyst noted, per Dividend Power.
Bridge City Bets Big on Healthcare, Dumps Aerospace Stake
Bridge City raised its Omnicell stake by 46.3% to 56,968 shares, valued at about $2.58 million. Omnicell reported strong Q1 2026 results and raised its full-year EBITDA guidance after launching its Titan XT platform. CEO Randall Lipps has called "autonomous medication management" the company's core growth engine for 2026, according to Business Wire. Omnicell carries a market cap of $1.72 billion and a P/E of 85.98.
On the other end, Bridge City cut its Albany International stake by 36.5%, keeping just 65,241 shares worth about $3.31 million. Albany has struggled with a fixed-price contract for the U.S. military's CH-53K helicopter program. CEO Gunnar Kleveland admitted the contract had "no path to profitability" without modifications, and the company booked a $147 million loss reserve adjustment in late 2025, according to Investing.com.
Plexus Insider Sells $814K in Shares Amid Bridge City Trim
Bridge City also trimmed its Plexus Corp. position by 14.2%, leaving it with 15,228 shares worth about $2.24 million. Around the same time, a Plexus insider made a notable exit. Victor (Pang Hau) Tan, the company's Regional President for Asia-Pacific, sold 3,000 shares on May 11 at $271.23 per share, totaling $813,690, according to MarketBeat. He still holds 10,457 shares after the sale.
Some analysts read insider sales like Tan's as a signal that executives see limited near-term upside. Bridge City's simultaneous reduction adds to that picture. Plexus operates in electronic contract manufacturing, a sector facing pressure from shifting supply chains and automation trends — the same trends pushing Bridge City toward healthcare technology like Omnicell.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
2
Reach
17
Topics
A
AnonymousAuthor
